Questionnaire

1. A placebo-controlled study of the nasal decongestant effect of a single dose of phenylephrine or pseudoephedrine in patients with intermittent AR found that:

2. A number of meta-analyses and systematic reviews have demonstrated that oral phenylephrine does not offer substantial relief from nasal congestion compared to placebo in adults:

3. Compared with fluticasone propionate nasal spray for the relief of nasal congestion in participants with documented AR, a single-dose oral loratadine-pseudoephedrine combination was associated with:

4. Pseudoephedrine is contraindicated in patients who have:

5. A direct sympathomimetic effect of pseudoephedrine is stimulation of:

6. Pseudoephedrine is recommended for the symptomatic treatment of:

7. The mechanism of action of loratadine gives rise to decreased:

8. The adverse effects of disturbed psychological performance and daytime sleepiness and fatigue have been reported by patients using oral pseudoephedrine for symptomatic relief of intermittent AR:

9. For a child aged 6-12 years, the maximum daily dose of oral pseudoephedrine is:

 10. Compared with participants using a once-daily combination formulation of loratadine-pseudoephedrine for the relief of moderate-to-severe intermittent AR symptoms, a double-blind placebo-controlled study found that participants using a twice-daily formulation reported significantly more: